Adaptive Biotechnologies get expanded medicare coverage of clonoSEQ for assessing measurable residual disease in mantle cell lymphoma: Seattle Saturday, November 9, 2024, 15:00 Hr ...

Good day and welcome to Adaptive Biotechnologies third quarter financial results. (Operator Instructions) As a reminder, this call may be recorded. I would like to turn the call over to Karina ...

Of those available for MRD testing, 92% achieved MRD negativity ... to potentially offering Anito-cel’s best-in-class profile to these late-stage multiple myeloma patients. Separately, we're pleased ...

An updated analysis from the pivotal ECHO phase III trial will further highlight the use of Calquence in combination with bendamustine and rituximab as a first-line treatment option by demonstrating ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

According to a new market research report, 'Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies.

Minimal residual disease (MRD): remaining microscopic traces of tumor cells ... of Bone Marrow Transplant and Cellular Therapies and director of the Multiple Myeloma Programs at Fox Chase Cancer ...

"In an incurable disease such as MCL, implementing ClonoSeq MRD assessment is essential not only to identify those patients at high risk of relapse but also for advancing patient-centric treatment ...